TriangleNCT00405756 · OUTCOME
Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- up to 165 weeks
What was measured
Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
Analysis population: Intent to treat population
Groups in this outcome
MPR+R
Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
MPR+p
Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
MPp+p
Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
| Group | Source count |
|---|---|
| MPR+R | 152 |
| MPR+p | 153 |
| MPp+p | 154 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| MPR+R | 148.1 | Not reported | 100.00 | NA | Upper limit not estimable because of the number of participants without progressive disease at data cut-off. |
| MPR+p | 62.7 | Not reported | 57.14 | 74.14 | Not reported |
| MPp+p | 61.3 | Not reported | 52.29 | 70.14 | Not reported |
Source statistical analyses
- ci Lower Limit
- 0.231
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 0.493
- group Ids
- OG000
- OG002
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- p Value
- <0.001
- p Value Comment
- The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.
- param Type
- Hazard Ratio (HR)
- param Value
- 0.337
- statistical Method
- Log Rank
- tested Non Inferiority
- false
- ci Lower Limit
- 0.284
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 0.603
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- p Value
- <0.001
- p Value Comment
- The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.
- param Type
- Hazard Ratio (HR)
- param Value
- 0.414
- statistical Method
- Log Rank
- tested Non Inferiority
- false
- ci Lower Limit
- 0.606
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.125
- group Ids
- OG001
- OG002
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- p Value
- 0.223
- p Value Comment
- The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.
- param Type
- Hazard Ratio (HR)
- param Value
- 0.826
- statistical Method
- Log Rank
- tested Non Inferiority
- false
Complete source fields
- analyses
- ci Lower Limit
- 0.231
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 0.493
- group Ids
- OG000
- OG002
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- p Value
- <0.001
- p Value Comment
- The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.
- param Type
- Hazard Ratio (HR)
- param Value
- 0.337
- statistical Method
- Log Rank
- tested Non Inferiority
- false
- ci Lower Limit
- 0.284
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 0.603
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- p Value
- <0.001
- p Value Comment
- The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.
- param Type
- Hazard Ratio (HR)
- param Value
- 0.414
- statistical Method
- Log Rank
- tested Non Inferiority
- false
- ci Lower Limit
- 0.606
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.125
- group Ids
- OG001
- OG002
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- p Value
- 0.223
- p Value Comment
- The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.
- param Type
- Hazard Ratio (HR)
- param Value
- 0.826
- statistical Method
- Log Rank
- tested Non Inferiority
- false
- classes
- categories
- measurements
- comment
- Upper limit not estimable because of the number of participants without progressive disease at data cut-off.
- group Id
- OG000
- lower Limit
- 100.00
- upper Limit
- NA
- value
- 148.1
- group Id
- OG001
- lower Limit
- 57.14
- upper Limit
- 74.14
- value
- 62.7
- group Id
- OG002
- lower Limit
- 52.29
- upper Limit
- 70.14
- value
- 61.3
- denoms
- counts
- group Id
- OG000
- value
- 152
- group Id
- OG001
- value
- 153
- group Id
- OG002
- value
- 154
- units
- Participants
- description
- Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
- id
- OG000
- title
- MPR+R
- description
- Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
- id
- OG001
- title
- MPR+p
- description
- Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
- id
- OG002
- title
- MPp+p
- param Type
- MEDIAN
- population Description
- Intent to treat population
- reporting Status
- POSTED
- time Frame
- up to 165 weeks
- title
- Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice